Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
Status:
Completed
Trial end date:
2017-02-08
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and the best dose of alisertib when given
together with gemcitabine hydrochloride in treating patients with solid tumors or pancreatic
cancer that is metastatic or cannot be removed by surgery. Alisertib may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Giving alisertib
with gemcitabine hydrochloride may be an effective treatment for solid tumors or pancreatic
cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Karen Kelly University of California, Davis
Collaborators:
Millennium Pharmaceuticals, Inc. National Cancer Institute (NCI) Takeda